Tagged with innovation

Biotech The CEO of Venter Pharma explains the challenges of bringing a diagnostic drug to the market, and how they hope to leverage the science behind their product, LacTEST, in various new forms and indications.   Before you came on board at Venter Pharma, the research for your product LacTEST was…

innovation Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research industry and stresses the importance of knowledge-sharing for success.   What have been some of the most important changes made…

innovation Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of the world for disruptive and incremental innovation.   What are the current trends in Korea’s pharmaceutical industry? The global market…

entrepreneurship Mauro Bono discusses the challenges of building a company from the interior of Argentina, and shares his assessment of the key issues driving and preventing change in the country’s pharmaceutical sector.   What are some of the challenges and opportunities associated with building a business in Cordoba, given that Argentina’s…

biotech The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million since 2006, and strives to deliver its pipeline of innovative medicines to treat seriously ill patients in Mexico.   You…

biotech The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million since 2006, and strives to deliver its pipeline of innovative medicines to treat seriously ill patients in Mexico.   You…

association On behalf of the chamber of industry that represents research-based pharma and biopharma companies in Argentina, Ernesto Felicio discusses the current challenges facing the industry, and the chambers current agenda for change.   To what extent has the environment for multinationals, or their role in the Argentinian pharmaceutical industry, significantly…

innovation The general manager of BI Algeria discusses how Algeria could benefit from participating in international clinical trials and describes how his company is adapting its offering to mirror the changing health profile of the nation which is currently undergoing a transition from infectious and transmissible disease to chronic and lifestyle illnesses.…

research The director general for Scientific Research and Technological Development discusses the authorities’ efforts to incentivize R&D and to harmonize sectoral development strategies to achieve national economic growth outcomes. He also identifies bottlenecks in the human capital base and the importance of raising the intellectual and scientific level of the local…

Bayer Bayer Malaysia’s managing director, Thomas Steffen, discusses the key differences and opportunities offered by the Malaysian market and calls for more information to help the promotion of oral contraception in order to strengthen women’s role in society. As you are managing the pharmaceutical business in both Malaysia and Singapore, how…

innovation Recognizing the value of innovation is fundamental for the success of every pharmaceutical company operating in Korea. Lee Sang-Suk, CEO of the Korean Research-based Pharmaceutical industry Association (KRPIA), demonstrates the commitment of multinationals to Korea to help illustrate the benefits of innovation that Koreans can access.     What is…

Sanofi The director general of the Argentina, Uruguay and Paraguay region for Sanofi discusses the strength of the Argentinian healthcare system and the key, but subdued, role that multinational pharmaceutical companies play within it.     As someone who comes from abroad, how would you describe the environment here for multinationals?…